Literature DB >> 4528778

The effects of arginine deficiency on lymphoma cells.

J M Storr, A F Burton.   

Abstract

When L5178Y and L1210 mouse lymphosarcoma cells were incubated with rat or beef liver arginase there was up to 100% cell destruction in 24 hours. This was reversed specifically with arginine and partially with arginino-succinic acid, citrulline and ornithine. The concentration of arginine was critical; at 8 μmol/l the cells remained viable and reversible inhibition could be shown; below this level cells died. L5178Y cells were grown in medium containing from 0 to 80 μmol/l arginine for 24 hours then transferred to fresh medium for 24 hours. Viable cell counts and mitotic indices were determined, and cells were pulsed with (3)H-thymidine, (3)H-uridine, (14)C-leucine and (14)C-arginine at various times. Thymidine uptake was affected most and preceded parallel changes in viable cell numbers. It was concluded that arginine is required by these cells even in a "resting" state and despite some evidence for their capacity to utilize precursors, the tumour cells underwent rapid and extensive destruction when available arginine was severely depleted.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4528778      PMCID: PMC2009188          DOI: 10.1038/bjc.1974.112

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Fractionation of the histones of the Walker 256 carcinosarcoma by combined chemical and chromatographic techniques.

Authors:  L S HNILICA; H BUSCH
Journal:  J Biol Chem       Date:  1963-03       Impact factor: 5.157

2.  Inhibition of growth of cultured mammalian cells by liver extracts.

Authors:  I LIEBERMAN; P OVE
Journal:  Biochim Biophys Acta       Date:  1960-02-12

3.  The oxidation of pyruvate in pigeon breast muscle.

Authors:  H A Krebs; L V Eggleston
Journal:  Biochem J       Date:  1940-03       Impact factor: 3.857

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Effect of arginine deficiency on synthesis of DNA and immunoglobulin receptor of Burkitt lymphoma cells.

Authors:  B O Osunkoya; W H Adler; R T Smith
Journal:  Nature       Date:  1970-07-25       Impact factor: 49.962

6.  Evidence that a rat liver "inhibitor" of the synthesis of DNA in cultured mammalian cells is arginase.

Authors:  R W Holley
Journal:  Biochim Biophys Acta       Date:  1967-09-26

7.  In vitro cytocidal effect of L-glutaminase on leukaemic lymphocytes.

Authors:  R Schrek; J S Holcenberg; J Roberts; W C Dolowy
Journal:  Nature       Date:  1971-07-23       Impact factor: 49.962

8.  Reversible inhibition of cell multiplication by a small class of liver proteins.

Authors:  J J Freed; S Sorof
Journal:  Biochem Biophys Res Commun       Date:  1966-01-04       Impact factor: 3.575

9.  Lymphocyte transformation by phytohemagglutinin. I. In Hodgkin's Disease.

Authors:  J W Thomas; W Boldt; G Horrocks; B Low
Journal:  Can Med Assoc J       Date:  1967-09-30       Impact factor: 8.262

10.  THE EFFECT OF ARGINASE ON THE RETARDATION OF TUMOUR GROWTH.

Authors:  S J BACH; D SWAINE
Journal:  Br J Cancer       Date:  1965-06       Impact factor: 7.640

View more
  16 in total

1.  Arginine decarboxylase from a Pseudomonas species.

Authors:  H J Rosenfeld; J Roberts
Journal:  J Bacteriol       Date:  1976-02       Impact factor: 3.490

Review 2.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

3.  Arginine deprivation and tumour cell death: arginase and its inhibition.

Authors:  Denys N Wheatley; Ruth Philip; Elaine Campbell
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 4.  Arginine catabolism, liver extracts and cancer.

Authors:  Denys N Wheatley; Elaine Campbell
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 5.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 6.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 7.  Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Authors:  Melissa M Phillips; Michael T Sheaff; Peter W Szlosarek
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

8.  Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.

Authors:  B Delage; P Luong; L Maharaj; C O'Riain; N Syed; T Crook; E Hatzimichael; A Papoudou-Bai; T J Mitchell; S J Whittaker; R Cerio; J Gribben; N Lemoine; J Bomalaski; C-F Li; S Joel; J Fitzgibbon; L-T Chen; P W Szlosarek
Journal:  Cell Death Dis       Date:  2012-07-05       Impact factor: 8.469

Review 9.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.

Authors:  Lihua Li; Yan Wang; Jun Chen; Bi Cheng; Jiehua Hu; Yuehua Zhou; Xin Gao; Liucun Gao; Xifan Mei; Meiyan Sun; Zhuomei Zhang; Haifeng Song
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.